Evaxion welcomes Per Norlén as new CEO

Denmark-based clinical-stage firm Evaxion Biotech (Nasdaq: EVAX), which specializes in the development of AI-driven immunotherapies, announced that its new chief executive Per Norlén joined the company on October 3.

Most recently, Dr Norlén was CEO of Targinta and chief medical officer of its wholly-owned Swedish subsidiary Xintela. Prior to that, Mr Norlén was the CEO and CMO at Alligator Bioscience. Dr Norlén is a board-certified physician and associate professor with more than 20 years in the biotech sector.

“Evaxion has emerged from being an under-the-radar start-up to becoming a clinical stage biotech company leading the development of tailored cancer immunotherapies, individually designed for each patient. I am convinced that Evaxion is on to something extremely important that holds the potential to become a game-changer for patients with metastatic cancer. During my previous career, I have always dreamt of making the perfect drug, and I feel enormously privileged to now be part of a team that I believe is doing just that. This is clearly within reach with a newly initiated Phase IIb trial in melanoma that will hopefully confirm the very promising phase 1 efficacy signals,” says Per Norlén.